Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Jul 28;2(9-10):467–478. doi: 10.1242/dmm.001438

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

PMC Copyright notice

Fig. 4. — FA rescues heart development of Wnt3A-exposed embryos immunostained with MF20 antibody. (A–C) Control embryonic hearts in whole mounts: (A) untreated control (Con) embryo; (B) FA exposure only, 2 μg/ml; and (C) FA exposure only, 10 μg/ml. HH stages 3+/4 embryos exposed to 2 ng/ml (D) or 10 ng/ml (G) of Wnt3A display abnormal heart development. FA supplementation at a concentration of 2 μg/ml rescues embryonic heart development at the 2 ng/ml Wnt3A concentration (E), but only partially rescues heart development in embryos exposed to 10 ng/ml of Wnt3A (H, left-looping heart). FA supplementation at a concentration of 10 μg/ml completely normalized heart development with either a low or high level of Wnt 3A exposure (F,I). (J) Bright-field view of the embryo shown in K, a negative control without primary antibody treatment. In all panels, the embryonic anterior is at the top. Bar, 275 μm.